Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT06088680 |
Other study ID # |
CIP-003 |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
September 26, 2023 |
Est. completion date |
July 30, 2024 |
Study information
Verified date |
February 2024 |
Source |
GLYCAR SA (Pty) Ltd |
Contact |
Philisile Nxumalo |
Phone |
27 12 667 1615 |
Email |
philisile[@]glycar.co.za |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
The overall purpose of this observational Post Market Clinical Follow Up (PMCF) study is to
ensure continued acceptability of the benefit risk ratio by assessment of safety and
performance, in patients undergoing cardiovascular repair or reconstruction surgery under
standard clinical care with the commercially available Glycar Pericardial Patch.
Description:
To comply with Medical Device Regulation (MDR) Post Market Clinical Follow Up (PMCF)
requirements through proactive ongoing assessment of the safety, efficacy, and performance of
the commercially available Glycar Pericardial Patch in patients undergoing cardiovascular
repair or reconstruction surgery.
This real-world evidence retrospective data collection single-arm multicentre, observational,
non-interventional study will enrol up to a minimum of 50 consecutive participants who meet
inclusion criteria, in 2-3 centres. The study is aimed at providing real-world evidence of
the Glycar Pericardial patch.
Retrospective data analysis will include collected clinical data from consecutive
participants with a minimum of 2 years follow up, meaning from 30 June 2020 and going back in
time. The quality of medical history being recorded is believed to be more reliable and
complete in the most recent years. Therefore, it was decided to start enrolling consecutive
participants in a reverse chronological order.